Towards Fully Automated Glucose Management: Insulin Delivery Algorithms, Better and Smarter Insulins, Second (and Third) Hormones, and Adjunctive Drugs
Join the American Diabetes Association's Diabetes Technology Interest Group for an ADA member-only live event on October 5th at 1pm ET.
Expert discussion on the potential for combining automated insulin delivery with more rapidly absorbed and cleared insulin, additional drugs delivered by the AID system such as glucagon and pramlintide, adjunctive drugs given by other routes including as SGLT-2 inhibitors and GLP-1 agonists, and the potential synergy between automated insulin delivery systems and “smart” insulins whose action is dependent on the blood glucose level.
Experts will summarize the data that is already available on these various approaches, discuss potential future approaches, and speculate on what can be achieved through the combination of these diabetes drugs and technologies to improve the lives of people with diabetes. Time will be set aside for questions and discussion with the audience.
Upon completion, participant will be able to:
• Articulate the limits of current AID systems and how modified insulins, second (or third) hormones, and adjunctive drugs may address these limitations.
• Explain the effects in clinical trials of combining AID with glucagon, pramlintide, SGLT-2 inhibitors, and GLP-1 agonists.
• Describe the two broad categories of “smart” insulins, and how they might be combined with automated insulin delivery to improve glycemic control.
• Ahmad Haidar, PhD, McGill University, Associate Professor, Department of Biomedical Engineering, Faculty of Medicine and Health Sciences
• Danny Hung-Chieh Chou, PhD, Stanford University, Assistant Professor of Pediatrics (Endocrinology) and Chemical and Systems Biology
• Steven Russell, MD, PhD, Harvard Medical School, Associate Professor of Medicine